Concepedia

James A. Milligan

JA

25

Publications

3.7K

Citations

22

H-Index

1973

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

James A. Milligan is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and biochemistry.

ORCID

Top concepts

Publications per year

1973–2017

25

Publications

25

Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists

Suzanne Mandala, Richard Hajdu, James D. Bergstrom et al. · Science · 2002 · 1.7K citations

, , +19

Immune Cell Regulation and Cardiovascular Effects of Sphingosine 1-Phosphate Receptor Agonists in Rodents Are Mediated via Distinct Receptor Subtypes

M J Forrest, S.-Y. Sun, Richard Hajdu et al. · Journal of Pharmacology and Experimental Therapeutics · 2004 · 332 citations

Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy

Robert W. Myers, Hong-Ping Guan, Juliann Ehrhart et al. · Science · 2017 · 329 citations

, , +23

Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies

Martha Kurtz, George K. Abruzzo, Amy Flattery et al. · Infection and Immunity · 1996 · 137 citations · Full text

, , +15

Khafrefungin, a Novel Inhibitor of Sphingolipid Synthesis

Suzanne Mandala, Rosemary Thornton, Mark Rosenbach et al. · Journal of Biological Chemistry · 1997 · 137 citations · Full text

Rows per page

1–5 of 25